Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tissue.
Hosted on MSN11mon
Aurion doses first subject in Phase I/II corneal oedema trial in CanadaThe company had received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its Vyznova cell therapy to treat bullous keratopathy of the cornea, in March last year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback